Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion ...

Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy ...

Halia Therapeutics has completed the enrolment in its Phase IIa trial of HT-6184 (Ofirnoflast) in those with lower-risk MDS.

Updated, longer-term results from the COMMANDS trial show a promising trend toward improved overall survival with ...

The global sales of anemia treatment are estimated to be worth USD 12,287.3 million in 2025 and are anticipated to reach a value of USD 23,903.5 million by 2035. Sales are projected to rise at a CAGR ...

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today ...

† Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92037, United States ‡ Genomics Institute of the Novartis Research Foundation, 10675 John ...

Panelists discuss how differentiating primary from secondary erythrocytosis is crucial in guiding treatment strategies, emphasizing the importance of addressing underlying causes such as chronic ...

Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs), whether defined as lack of hemoglobin response to typical ESA doses or need for higher ESA doses to reach hemoglobi ...

Panelists discuss how hepcidin mimetics like rusfertide offer a novel approach to managing polycythemia vera (PV) by ...

Conclusion: This study enhances our understanding of the postnatal decline of hepatic haematopoiesis in human newborns, highlighting the differential regulation of erythropoiesis and granulopoiesis ...

Erythropoietin is an endogenous hormone of glicoproteic nature secreted by the kidneys and is the main regulator of the erythropoiesis. An alteration in its production generates a disturbance in the ...